The Mechanism of Enhancing the Anti-tumor Effects of CAR-T on PC by Gut Microbiota Regulation
Study on the Mechanism of Enhancing the Anti-tumor Effects of Human Chimeric Antigen Receptors T Cells on Pancreatic Cancer by Gut Microbiota Regulation
Sponsor: First Affiliated Hospital of Harbin Medical University
This observational or N/A phase trial investigates CAR-T and Gut Microbiota and is currently ongoing. First Affiliated Hospital of Harbin Medical University leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Dec 2021 — Feb 2023 [monthly]
Recruiting
-
Jan 2021 — Dec 2021 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Jan 2020 — Nov 2020 [monthly]
Recruiting
First recorded
Oct 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- First Affiliated Hospital of Harbin Medical University
For direct contact, visit the study record on ClinicalTrials.gov .